Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?Carter BZ; Mak DH; Cortes J; Andreeff MSemin Hematol 2010[Oct]; 47 (4): 362-70Chronic myeloid leukemia (CML) is a clonal multistep myeloproliferative disease originating from and ultimately sustained by a rare population of BCR-ABL(+) cells with multilineage stem cell properties. Imatinib, the most successful of molecular targeted therapies, has revolutionized treatment of patients with CML. Despite this achievement, CML is often not curable, largely due to the innate insensitivity of CML stem cells, particularly when in a quiescent state. This failure of not only imatinib but also the second-generation tyrosine kinase inhibitors (TKIs) frequently leads to relapse upon drug discontinuation. Thus, any curative therapy must eliminate CML stem cells. A comprehensive understanding of the biological properties of CML stem cells and an elucidation of the molecular mechanisms and signaling pathways enabling these CML stem cells to self-renew, combined with insight into the regulation of apoptosis signaling and the mechanisms governing the interaction of CML stem cells with their bone marrow microenvironment, will facilitate the development of therapies for targeting these cells. Here, we discuss the biological properties of CML stem cells and potential strategies to eliminate them.|Antineoplastic Agents/therapeutic use[MESH]|Benzamides[MESH]|Humans[MESH]|Imatinib Mesylate[MESH]|Interferon-alpha/therapeutic use[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/immunology/*pathology/*therapy[MESH]|Neoplastic Stem Cells/drug effects/*pathology[MESH]|Piperazines/therapeutic use[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH]|Pyrimidines/therapeutic use[MESH]|Signal Transduction/drug effects[MESH] |